Table 5. Odds ratios of A) virological failure (non-SVR12).
B) treatment failure (TF) from fitting a logistic regression model.
|
A) non-SVR12 |
OR of DAA failure from fitting a logistic regression model | |||||
| Characteristics | Virological failure | SVR | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
| N = 50 | N = 545 | |||||
| Age, years, n (%) | ||||||
| 0–50 | 13 (26.0) | 160 (29.4) | 1.0 | 1.0 | ||
| 51+ | 37 (74.0) | 385 (70.6) | 1.0 (0.5, 2.1) | 0.9 | 1.0 (0.5, 2.0) | 0.9 |
| Gender, n (%) | ||||||
| Male | 44 (88.0) | 424 (77.8) | 1.0 | 1.0 | ||
| Female | 6 (12.0) | 121 (22.2) | 0.5 (0.2, 1.1) | 0.1 | 0.5 (0.2, 1.2) | 0.1 |
| Ribavirin, n (%) | ||||||
| Not used | 23 (46.0) | 248 (45.5) | 1.0 | 1.0 | ||
| Used | 27 (54.0) | 297 (54.5) | 1.0 (0.5, 1.7) | 0.9 | 1.0 (0.6, 1.8) | 1.0 |
| HCV Genotype, n (%) | ||||||
| 1,2,4,other | 36 (72.0) | 439 (80.6) | 1.0 | 1.0 | ||
| 3 | 14 (28.0) | 106 (19.4) | 1.6 (0.8, 3.1) | 0.1 | 1.2 (0.6, 2.4) | 0.7 |
| Sub-optimal DAA, n (%) | ||||||
| No | 35 (70.0) | 467 (85.7) | 1.0 | 1.0 | ||
| Yes | 15 (30.0) | 78 (14.3) | 2.6 (1.3, 4.9) | 0.005 | 2.5 (1.2, 5.1) | 0.011 |
| CD4 count nadir, cells/mm3, n (%) | ||||||
| 0–100 | 11 (22.0) | 144 (26.4) | 1.0 | 1.0 | ||
| 101+ | 39 (78.0% | 401 (73.6) | 0.79 (0.39, 1.57) | 0 | 0.8 (0.4, 1.6) | 0.537 |
| Decompensated cirrhosis, n (%) | ||||||
| No | 42 (84.0) | 494 (90.6) | 1.00 | 1.0 | ||
| Yes | 8 (16.0) | 51 (9.4) | 1.8 (0.8, 4.1) | 0.1 | 1.8 (0.8, 4.2) | 0.2 |
| Diabetes, n (%) | ||||||
| No | 43 (86.0) | 498 (91.4) | 1.0 | 1.0 | ||
| Yes | 7 (14.0) | 47 (8.6) | 1.7 (0.7, 4.0) | 0.2 | 1.5 (0.6, 3.7) | 0.4 |
| B) TF | OR of DAA failure from fitting a logistic regression model | |||||
| Characteristics | Treatment failure | SVR | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
| N = 61 | N = 545 | |||||
| Age, years, n (%) | ||||||
| 0–50 | 19 (31.1) | 160 (29.4) | 1.0 | 1.0 | ||
| 51+ | 42 (68.9) | 385 (70.6) | 0.7 (0.4, 1.3) | 0.3 | 0.8 (0.4, 1.5) | 0.5 |
| Gender, n (%) | ||||||
| Male | 52 (85.2) | 424 (77.8) | 1.0 | 1.0 | ||
| Female | 9 (14.8) | 121 (22.2) | 0.6 (0.3, 1.3) | 0.2 | 0.6 (0.3, 1.3) | 0.2 |
| Ribavirin, n (%) | ||||||
| Not used | 27 (44.3) | 248 (45.5) | 1.0 | 1.0 | ||
| Used | 34 (55.7) | 297 (54.5) | 1.0 (0.6, 1.8) | 0.8 | 1.1 (0.6, 1.8) | 0.8 |
| HCV Genotype, n (%) | ||||||
| 1,2,4,other | 44 (72.1) | 439 (80.6) | 1.0 | 1.0 | ||
| 3 | 17 (27.9) | 106 (19.4) | 1.6 (0.9, 2.9) | 0.1 | 1.3 (0.7, 2.4) | 0.5 |
| Sub-optimal DAA, n (%) | ||||||
| No | 44 (72.1) | 467 (85.7) | 1.0 | 1.0 | ||
| Yes | 17 (27.9) | 78 (14.3) | 2.3 (1.3, 4.2) | 0.007 | 2.2 (1.1, 4.2) | 0.02 |
| CD4 count nadir, cells/mm3, n (%) | ||||||
| 0–100 | 15 (24.6) | 144 (26.4) | 1.0 | 1.0 | ||
| 101+ | 46 (75.4) | 401 (73.6) | 0.9 (0.5, 1.7) | 0.8 | 0.9 (0.5, 1.7) | 0.8 |
| Decompensated cirrhosis, n (%) | ||||||
| No | 51 (83.6) | 494 (90.6) | 1.0 | 1.0 | ||
| Yes | 10 (16.4) | 51 (9.4) | 1.9 (0.9, 4.0) | 0.09 | 1.8 (0.8, 4.0) | 0.1 |
| Diabetes, n (%) | ||||||
| No | 53 (86.9) | 498 (91.4) | 1.0 | 1.0 | ||
| Yes | 8 (13.1) | 47 (8.6) | 1.6 (0.7, 3.6) | 0.2 | 1.4 (0.6, 3.2) | 0.4 |
Adjusted OR: adjusted for all factors examined in table.